Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma

被引：4

作者：

Kuzuya, Teiji ^{[1
]}

Kawabe, Naoto ^{[1
]}

Muto, Hisanori ^{[1
]}

Wada, Yuryo ^{[1
]}

Komura, Gakushi ^{[1
]}

Nakano, Takuji ^{[1
]}

Tanaka, Hiroyuki ^{[1
]}

Nakaoka, Kazunori ^{[1
]}

Ohno, Eizaburo ^{[1
]}

Funasaka, Kohei ^{[1
]}

Nagasaka, Mitsuo ^{[1
]}

Miyahara, Ryoji ^{[1
]}

Hirooka, Yoshiki ^{[1
]}

机构：

[1] Fujita Hlth Univ, Dept Gastroenterol & Hepatol, 1-98 Dengakugakubo,Kutsukake Cho, Toyoake 4701192, Japan

来源：

CURRENT ONCOLOGY | 2024年 / 31卷 / 08期

关键词：

hepatocellular carcinoma; durvalumab; tremelimumab; antitumor response; alpha-fetoprotein; des-gamma-carboxy prothrombin; LYMPHOCYTE RATIO; BEVACIZUMAB; SORAFENIB; LENVATINIB; BIOMARKER; EFFICACY;

D O I：

10.3390/curroncol31080315

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The relationship between antitumor response and tumor marker changes was evaluated in patients with advanced hepatocellular carcinoma treated with durvalumab plus tremelimumab (Dur/Tre). Forty patients were enrolled in this retrospective evaluation of treatment outcomes. According to the Response Evaluation Criteria for Solid Tumors version 1.1 at 8 weeks, the objective response (OR) rate was 25% and the disease control (DC) rate was 57.5%. The median alpha-fetoprotein (AFP) ratio at 4 weeks was 0.39 in patients who achieved OR at 8 weeks (8W-OR group), significantly lower than the 1.08 in the non-8W-OR group (p = 0.0068); however, it was 1.22 in patients who did not achieve DC at 8 weeks (non-8W-DC group), significantly higher than the 0.53 in the 8W-DC group (p = 0.0006). Similarly, the median des-gamma-carboxy-prothrombin (DCP) ratio at 4 weeks was 0.15 in the 8W-OR group, significantly lower than the 1.46 in the non-8W-OR group (p < 0.0001); however, it was 1.23 in the non-8W-DC group, significantly higher than the 0.49 in the 8W-DC group (p = 0.0215). Early changes in tumor markers after Dur/Tre initiation were associated with antitumor response. In particular, changes in AFP and DCP at 4 weeks may offer useful biomarkers for early prediction of both response and progressive disease following Dur/Tre.

引用

页码：4225 / 4240

页数：16

共 32 条

[31] Changes in alpha-fetoprotein across the systemic therapy continuum in advanced hepatocellular carcinoma-a real-world, multicenter study [J].

Li, Michael ;

Hannan, Lindsay M. ;

Goyal, Lipika ;

Bocobo, Andrea G. ;

Parks, Anna L. ;

Bauer, Kelly ;

Baiev, Islam ;

Dinicola, Caroline ;

Gordan, John D. ;

Venook, Alan P. ;

Harris, William P. ;

Bracci, Paige ;

Kelley, Robin K. .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16

[32] Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein [J].

Kinami, Takahiro ;

Amioka, Kei ;

Kawaoka, Tomokazu ;

Uchikawa, Shinsuke ;

Yamasaki, Shintaro ;

Kosaka, Masanari ;

Johira, Yusuke ;

Yano, Shigeki ;

Naruto, Kensuke ;

Ando, Yuwa ;

Yamaoka, Kenji ;

Fujii, Yasutoshi ;

Fujino, Hatsue ;

Nakahara, Takashi ;

Ono, Atsushi ;

Murakami, Eisuke ;

Okamoto, Wataru ;

Yamauchi, Masami ;

Miki, Daiki ;

Tsuge, Masataka ;

Imamura, Michio ;

Aikata, Hiroshi ;

Oka, Shiro .

CANCERS, 2023, 15 (08)

← 1 2 3 4 →